Eurofins Scientific SEERFSF +3.01%77 PS Ratio is 1.75 as of Jun. 27, 2026, which is 18% below its 10-year median of 2.13. GuruFocus rates ERFSF with a GF Score™ of 77/100 and a GF Value™ of $77.44 (Fairly Valued). The stock has 7 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks better than 67.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eurofins Scientific SE's share price is $79.77.
Eurofins Scientific SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $45.48. Hence, Eurofins Scientific SE's PS Ratio for today is 1.75.
Warning Sign:
Eurofins Scientific SE stock PS Ratio (=1.76) is close to 3-year high of 1.92.
The historical rank and industry rank for Eurofins Scientific SE's PS Ratio or its related term are showing as below:
ERFSF'
s PS Ratio Range Over the Past 10 Years
Min: 1.32 Med: 2.13 Max: 4.52
Current: 1.76
During the past 13 years, Eurofins Scientific SE's highest PS Ratio was 4.52. The lowest was 1.32. And the median was 2.13.
ERFSF's PS Ratio is ranked better than 67.16% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.78
vs ERFSF: 1.76
During the past 12 months, the average Revenue per Share Growth Rate of Eurofins Scientific SE was 9.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 5.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.30% per year.
During the past 13 years, Eurofins Scientific SE's highest 3-Year average Revenue per Share Growth Rate was 38.40% per year. The lowest was 2.20% per year. And the median was 18.40% per year.
Back to Basics: PS Ratio
Eurofins Scientific SE (OTCPK:ERFSF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Eurofins Scientific SE's Share Price of today is $79.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Eurofins Scientific SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $45.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Eurofins Scientific SE (ERFSF) has a PS Ratio of 1.75 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eurofins Scientific SE and its competitors. This is 18% below median its historical median of 2.13. Over the past decade, Eurofins Scientific SE's PS Ratio has ranged from 1.32 to 4.52. According to the industry distribution chart, Eurofins Scientific SE ranks #66 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 32.8%.
Is Eurofins Scientific SE's PS Ratio too high?
Eurofins Scientific SE's current PS Ratio of 1.75 is 18% below median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 4.52. The Medical Diagnostics & Research industry median PS Ratio is 2.78. Eurofins Scientific SE's value of 1.75 is 37.1% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #66 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #66 out of 201 companies for PS Ratio. This puts Eurofins Scientific SE in the upper half of its industry. The industry median PS Ratio is 2.78. Eurofins Scientific SE's value of 1.75 is 37.1% below this benchmark. Historically, Eurofins Scientific SE's own PS Ratio has ranged from 1.32 to 4.52 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 2.78, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.78, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current PS Ratio of 1.75 is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current PS Ratio is 1.75, which is 18% below median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $77.44, compared to a current price of $79.77 — trading 3% above its estimated fair value. The current PS Ratio is 1.75, which is 18% below median its 10-year median of 2.13 and 37.1% below the Medical Diagnostics & Research industry median of 2.78. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current PS Ratio is 1.75 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $79.77 is trading 3% above its estimated GF Value™ of $77.44.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
PS Ratio: 1.75 (18% below median its 10-year median of 2.13)
GF Value™: $77.44 vs. price of $79.77 (3% above fair value)
Industry Position: 37.1% below the Medical Diagnostics & Research median (#66 of 201)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
